Revascularization benefits

New York, July 5, 2000 (Praxis Press) The 6-month results of the FRISC II (Fast Revascularisation during Instability in Coronary artery disease) invasive trial show a reduction in the composite endpoint of death or myocardial infarction, contradicting previous large-scale randomized trials. The recent one-year follow-up of this randomized trial published in the Lancet confirms that the invasive strategy rapidly transforms unstable coronary-artery disease into a stable condition, lowering long-te

July 6, 2000

New York, July 5, 2000 (Praxis Press) The 6-month results of the FRISC II (Fast Revascularisation during Instability in Coronary artery disease) invasive trial show a reduction in the composite endpoint of death or myocardial infarction, contradicting previous large-scale randomized trials. The recent one-year follow-up of this randomized trial published in the Lancet confirms that the invasive strategy rapidly transforms unstable coronary-artery disease into a stable condition, lowering long-term mortality and reintervention rate, myocardial-infarction risk, and the recurrence of angina and ischemia (see paper). Compared with non-invasive treatment strategy in 100 patients, the invasive approach saves 1.7 lives, prevents 2.0 non-fatal myocardial infarctions, and 20 re-admissions. These findings strongly suggest revascularization as the treatment of choice for most patients with unstable CAD with ischemia, or biochemical markers of myocardial damage.

Popular Now

  1. Major German Universities Cancel Elsevier Contracts
  2. Running on Empty
    Features Running on Empty

    Regularly taking breaks from eating—for hours or days—can trigger changes both expected, such as in metabolic dynamics and inflammation, and surprising, as in immune system function and cancer progression.

  3. Most of Human Genome Nonfunctional: Study
  4. Identifying Predatory Publishers
AAAS